← Back to Search

Bi-specific Antibody

Epcoritamab for Chronic Lymphocytic Leukemia and Richter Syndrome

Phase 1
Waitlist Available
Led By Clare C Sun, M.D.
Research Sponsored by National Heart, Lung, and Blood Institute (NHLBI)
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up up to 5 years
Awards & highlights
No Placebo-Only Group

Summary

"This trial aims to study how a new drug called epcoritamab affects the body by analyzing samples from lymph nodes, bone marrow, and blood of participants in a clinical trial. Researchers will

Who is the study for?
This trial is specifically for individuals with certain blood cancers, including Chronic Lymphocytic Leukemia and Richter Syndrome. Participants are being invited to join the study, which will involve close monitoring of their response to a new treatment.
What is being tested?
The focus of this trial is on epcoritamab, an experimental medication designed to engage the immune system in fighting cancer. The study involves collecting samples from patients before and during treatment to understand how the drug affects cancer cells.
What are the potential side effects?
As this summary does not provide specific side effects of epcoritamab, it's important for participants to discuss potential risks with researchers. Generally, immunotherapies can cause reactions at infusion sites, flu-like symptoms, fatigue or allergic responses.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~up to 5 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and up to 5 years for reporting.

Treatment Details

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: epcoritamabExperimental Treatment1 Intervention
Samples from subjects receiving epcoritamab on another clinical trial GCT3013-03 will be collected.

Find a Location

Who is running the clinical trial?

National Heart, Lung, and Blood Institute (NHLBI)Lead Sponsor
3,936 Previous Clinical Trials
47,792,623 Total Patients Enrolled
Clare C Sun, M.D.Principal InvestigatorNational Heart, Lung, and Blood Institute (NHLBI)
4 Previous Clinical Trials
1,158 Total Patients Enrolled
~20 spots leftby Jul 2027
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top